MapLight Therapeutics (MPLT) EBIT (2024 - 2025)
MapLight Therapeutics recorded quarterly EBIT of -$83.4 million in Q4 2025, down 164.71% quarter-over-quarter from -$31.5 million in Q3 2025, and down 266.06% year-over-year from $50.2 million in Q4 2024.
MapLight Therapeutics' EBIT history runs 2 years deep, the most recent figure standing at -$83.4 million for Q4 2025.
- In Q4 2025, EBIT fell 266.06% year-over-year to -$83.4 million; the TTM figure through Dec 2025 stood at -$158.5 million (changed N/A YoY), while the FY2025 annual figure was -$169.1 million, down 103.85% from the prior year.
- EBIT came in at -$83.4 million for Q4 2025 at MapLight Therapeutics, down from -$31.5 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$20.9 million in Q3 2024 to a low of -$83.4 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 268.64 Mn |
| 10 | MapLight Therapeutics | 254.43 Mn | 254.43 Mn | - | -83.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -83.38 Mn |
| Sep 30, 2025 | -31.50 Mn |
| Dec 31, 2024 | -22.78 Mn |
| Sep 30, 2024 | -20.89 Mn |